nodes	percent_of_prediction	percent_of_DWPC	metapath
Glimepiride—CYP2C9—Capecitabine—esophageal cancer	0.2	0.665	CbGbCtD
Glimepiride—CYP2C9—Cisplatin—esophageal cancer	0.101	0.335	CbGbCtD
Glimepiride—KCNJ1—Inwardly rectifying K+ channels—GNG7—esophageal cancer	0.0178	0.0812	CbGpPWpGaD
Glimepiride—Hepatitis cholestatic—Capecitabine—esophageal cancer	0.0128	0.0276	CcSEcCtD
Glimepiride—Allergic cutaneous angiitis—Methotrexate—esophageal cancer	0.012	0.026	CcSEcCtD
Glimepiride—Inappropriate antidiuretic hormone secretion—Cisplatin—esophageal cancer	0.012	0.026	CcSEcCtD
Glimepiride—Reaction gastrointestinal—Methotrexate—esophageal cancer	0.0115	0.0248	CcSEcCtD
Glimepiride—Diabetic—Methotrexate—esophageal cancer	0.0115	0.0248	CcSEcCtD
Glimepiride—Disorder sight—Capecitabine—esophageal cancer	0.0108	0.0234	CcSEcCtD
Glimepiride—Paresis—Methotrexate—esophageal cancer	0.0105	0.0227	CcSEcCtD
Glimepiride—ABCC8—Inwardly rectifying K+ channels—GNG7—esophageal cancer	0.00909	0.0415	CbGpPWpGaD
Glimepiride—ABCC8—ABC-family proteins mediated transport—ABCC2—esophageal cancer	0.00888	0.0406	CbGpPWpGaD
Glimepiride—KCNJ11—Inwardly rectifying K+ channels—GNG7—esophageal cancer	0.00881	0.0402	CbGpPWpGaD
Glimepiride—Aphasia—Capecitabine—esophageal cancer	0.00793	0.0171	CcSEcCtD
Glimepiride—Leukocytoclastic vasculitis—Methotrexate—esophageal cancer	0.0078	0.0169	CcSEcCtD
Glimepiride—ABCC8—FOXA2 and FOXA3 transcription factor networks—ALDOB—esophageal cancer	0.00757	0.0345	CbGpPWpGaD
Glimepiride—KCNJ11—FOXA2 and FOXA3 transcription factor networks—ALDOB—esophageal cancer	0.00734	0.0335	CbGpPWpGaD
Glimepiride—KCNJ1—Potassium Channels—GNG7—esophageal cancer	0.00702	0.0321	CbGpPWpGaD
Glimepiride—Chlorpropamide—PTGS1—esophageal cancer	0.00672	0.369	CrCbGaD
Glimepiride—Eruption—Methotrexate—esophageal cancer	0.00622	0.0135	CcSEcCtD
Glimepiride—Glyburide—ABCC2—esophageal cancer	0.00599	0.33	CrCbGaD
Glimepiride—Aphasia—Methotrexate—esophageal cancer	0.0059	0.0128	CcSEcCtD
Glimepiride—Hyperbilirubinaemia—Capecitabine—esophageal cancer	0.00565	0.0122	CcSEcCtD
Glimepiride—Haemolytic anaemia—Cisplatin—esophageal cancer	0.00561	0.0121	CcSEcCtD
Glimepiride—Nocturia—Capecitabine—esophageal cancer	0.00554	0.012	CcSEcCtD
Glimepiride—Cerebrovascular accident—Cisplatin—esophageal cancer	0.00517	0.0112	CcSEcCtD
Glimepiride—Hyponatraemia—Cisplatin—esophageal cancer	0.00508	0.011	CcSEcCtD
Glimepiride—CYP2C9—Synthesis of epoxy (EET) and dihydroxyeicosatrienoic acids (DHET)—CYP1B1—esophageal cancer	0.00503	0.023	CbGpPWpGaD
Glimepiride—CYP2C9—CYP2E1 reactions—CYP2A6—esophageal cancer	0.00484	0.0221	CbGpPWpGaD
Glimepiride—ABCC8—ABC-family proteins mediated transport—ABCB1—esophageal cancer	0.00471	0.0215	CbGpPWpGaD
Glimepiride—CYP2C9—Synthesis of (16-20)-hydroxyeicosatetraenoic acids (HETE)—CYP1B1—esophageal cancer	0.00458	0.0209	CbGpPWpGaD
Glimepiride—Mental disability—Capecitabine—esophageal cancer	0.00446	0.00965	CcSEcCtD
Glimepiride—Speech disorder—Methotrexate—esophageal cancer	0.00445	0.00962	CcSEcCtD
Glimepiride—ABCC8—Regulation of insulin secretion—GNG7—esophageal cancer	0.00439	0.02	CbGpPWpGaD
Glimepiride—Diabetes mellitus—Capecitabine—esophageal cancer	0.00429	0.00928	CcSEcCtD
Glimepiride—Hepatic function abnormal—Capecitabine—esophageal cancer	0.00427	0.00924	CcSEcCtD
Glimepiride—Sweating increased—Cisplatin—esophageal cancer	0.00426	0.00922	CcSEcCtD
Glimepiride—KCNJ11—Regulation of insulin secretion—GNG7—esophageal cancer	0.00425	0.0194	CbGpPWpGaD
Glimepiride—Hyperbilirubinaemia—Methotrexate—esophageal cancer	0.00421	0.0091	CcSEcCtD
Glimepiride—Pancytopenia—Cisplatin—esophageal cancer	0.00416	0.00899	CcSEcCtD
Glimepiride—Hepatic failure—Capecitabine—esophageal cancer	0.00415	0.00898	CcSEcCtD
Glimepiride—Haemolytic anaemia—Capecitabine—esophageal cancer	0.00413	0.00894	CcSEcCtD
Glimepiride—Hot flush—Capecitabine—esophageal cancer	0.00399	0.00863	CcSEcCtD
Glimepiride—Increased appetite—Capecitabine—esophageal cancer	0.00397	0.00859	CcSEcCtD
Glimepiride—Menopausal symptoms—Capecitabine—esophageal cancer	0.00395	0.00855	CcSEcCtD
Glimepiride—Vasculitis—Methotrexate—esophageal cancer	0.00392	0.00848	CcSEcCtD
Glimepiride—Dermatitis bullous—Capecitabine—esophageal cancer	0.0039	0.00845	CcSEcCtD
Glimepiride—Cerebrovascular accident—Capecitabine—esophageal cancer	0.00381	0.00824	CcSEcCtD
Glimepiride—Hyponatraemia—Capecitabine—esophageal cancer	0.00375	0.0081	CcSEcCtD
Glimepiride—Pain in extremity—Capecitabine—esophageal cancer	0.00373	0.00807	CcSEcCtD
Glimepiride—Aplastic anaemia—Methotrexate—esophageal cancer	0.00359	0.00777	CcSEcCtD
Glimepiride—ABCC8—Potassium Channels—GNG7—esophageal cancer	0.00359	0.0164	CbGpPWpGaD
Glimepiride—Bradycardia—Cisplatin—esophageal cancer	0.00357	0.00771	CcSEcCtD
Glimepiride—Coma—Methotrexate—esophageal cancer	0.0035	0.00756	CcSEcCtD
Glimepiride—KCNJ11—Potassium Channels—GNG7—esophageal cancer	0.00348	0.0159	CbGpPWpGaD
Glimepiride—ABCC8—Integration of energy metabolism—GNG7—esophageal cancer	0.00345	0.0158	CbGpPWpGaD
Glimepiride—Visual impairment—Cisplatin—esophageal cancer	0.00338	0.0073	CcSEcCtD
Glimepiride—KCNJ11—Integration of energy metabolism—GNG7—esophageal cancer	0.00335	0.0153	CbGpPWpGaD
Glimepiride—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.00329	0.00712	CcSEcCtD
Glimepiride—Chlorpropamide—ABCB1—esophageal cancer	0.00326	0.18	CrCbGaD
Glimepiride—Abdominal distension—Capecitabine—esophageal cancer	0.00325	0.00702	CcSEcCtD
Glimepiride—Influenza—Capecitabine—esophageal cancer	0.00323	0.00698	CcSEcCtD
Glimepiride—Diabetes mellitus—Methotrexate—esophageal cancer	0.00319	0.00691	CcSEcCtD
Glimepiride—Angina pectoris—Capecitabine—esophageal cancer	0.00314	0.0068	CcSEcCtD
Glimepiride—Sweating increased—Capecitabine—esophageal cancer	0.00314	0.0068	CcSEcCtD
Glimepiride—Arrhythmia—Cisplatin—esophageal cancer	0.00313	0.00677	CcSEcCtD
Glimepiride—Hepatic failure—Methotrexate—esophageal cancer	0.00309	0.00669	CcSEcCtD
Glimepiride—KCNJ1—Neuronal System—GNG7—esophageal cancer	0.00307	0.014	CbGpPWpGaD
Glimepiride—Pancytopenia—Capecitabine—esophageal cancer	0.00306	0.00663	CcSEcCtD
Glimepiride—Erythema—Cisplatin—esophageal cancer	0.00305	0.00659	CcSEcCtD
Glimepiride—Malnutrition—Cisplatin—esophageal cancer	0.00305	0.00659	CcSEcCtD
Glimepiride—CYP2C9—Xenobiotics—CYP2A6—esophageal cancer	0.003	0.0137	CbGpPWpGaD
Glimepiride—Photosensitivity reaction—Capecitabine—esophageal cancer	0.00294	0.00637	CcSEcCtD
Glimepiride—Weight increased—Capecitabine—esophageal cancer	0.00294	0.00635	CcSEcCtD
Glimepiride—CYP2C9—Tamoxifen metabolism—CYP2A6—esophageal cancer	0.00288	0.0132	CbGpPWpGaD
Glimepiride—Vision blurred—Cisplatin—esophageal cancer	0.00287	0.00621	CcSEcCtD
Glimepiride—KCNJ1—Neuronal System—ALDH2—esophageal cancer	0.00287	0.0131	CbGpPWpGaD
Glimepiride—Tremor—Cisplatin—esophageal cancer	0.00286	0.00618	CcSEcCtD
Glimepiride—Stevens-Johnson syndrome—Capecitabine—esophageal cancer	0.00285	0.00617	CcSEcCtD
Glimepiride—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00283	0.00613	CcSEcCtD
Glimepiride—Anaemia—Cisplatin—esophageal cancer	0.00282	0.00609	CcSEcCtD
Glimepiride—Jaundice—Capecitabine—esophageal cancer	0.0028	0.00606	CcSEcCtD
Glimepiride—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP26A1—esophageal cancer	0.00275	0.0126	CbGpPWpGaD
Glimepiride—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—NR1I2—esophageal cancer	0.00275	0.0126	CbGpPWpGaD
Glimepiride—Leukopenia—Cisplatin—esophageal cancer	0.00273	0.0059	CcSEcCtD
Glimepiride—Agranulocytosis—Capecitabine—esophageal cancer	0.00268	0.0058	CcSEcCtD
Glimepiride—Convulsion—Cisplatin—esophageal cancer	0.00264	0.00571	CcSEcCtD
Glimepiride—Bradycardia—Capecitabine—esophageal cancer	0.00263	0.00568	CcSEcCtD
Glimepiride—Anxiety—Cisplatin—esophageal cancer	0.00259	0.00559	CcSEcCtD
Glimepiride—Hepatitis—Capecitabine—esophageal cancer	0.00258	0.00558	CcSEcCtD
Glimepiride—CYP2C9—Constitutive Androstane Receptor Pathway—ABCC2—esophageal cancer	0.00258	0.0118	CbGpPWpGaD
Glimepiride—Anaphylactic shock—Cisplatin—esophageal cancer	0.00249	0.00538	CcSEcCtD
Glimepiride—Visual impairment—Capecitabine—esophageal cancer	0.00249	0.00538	CcSEcCtD
Glimepiride—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCC2—esophageal cancer	0.00245	0.0112	CbGpPWpGaD
Glimepiride—Erythema multiforme—Capecitabine—esophageal cancer	0.00244	0.00528	CcSEcCtD
Glimepiride—Thrombocytopenia—Cisplatin—esophageal cancer	0.00244	0.00527	CcSEcCtD
Glimepiride—Tachycardia—Cisplatin—esophageal cancer	0.00243	0.00525	CcSEcCtD
Glimepiride—Hyperhidrosis—Cisplatin—esophageal cancer	0.00241	0.0052	CcSEcCtD
Glimepiride—Eosinophilia—Methotrexate—esophageal cancer	0.00238	0.00514	CcSEcCtD
Glimepiride—Anorexia—Cisplatin—esophageal cancer	0.00237	0.00513	CcSEcCtD
Glimepiride—CYP2C9—Tamoxifen metabolism—CYP1B1—esophageal cancer	0.00233	0.0106	CbGpPWpGaD
Glimepiride—Hypotension—Cisplatin—esophageal cancer	0.00233	0.00503	CcSEcCtD
Glimepiride—Arrhythmia—Capecitabine—esophageal cancer	0.00231	0.00499	CcSEcCtD
Glimepiride—Pancytopenia—Methotrexate—esophageal cancer	0.00228	0.00493	CcSEcCtD
Glimepiride—Erythema—Capecitabine—esophageal cancer	0.00225	0.00486	CcSEcCtD
Glimepiride—Malnutrition—Capecitabine—esophageal cancer	0.00225	0.00486	CcSEcCtD
Glimepiride—Paraesthesia—Cisplatin—esophageal cancer	0.00223	0.00483	CcSEcCtD
Glimepiride—Dyspnoea—Cisplatin—esophageal cancer	0.00222	0.0048	CcSEcCtD
Glimepiride—Glyburide—ABCB1—esophageal cancer	0.0022	0.121	CrCbGaD
Glimepiride—Photosensitivity reaction—Methotrexate—esophageal cancer	0.00219	0.00474	CcSEcCtD
Glimepiride—Decreased appetite—Cisplatin—esophageal cancer	0.00216	0.00468	CcSEcCtD
Glimepiride—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.00215	0.00465	CcSEcCtD
Glimepiride—Drowsiness—Methotrexate—esophageal cancer	0.00214	0.00463	CcSEcCtD
Glimepiride—Stevens-Johnson syndrome—Methotrexate—esophageal cancer	0.00212	0.00459	CcSEcCtD
Glimepiride—Vision blurred—Capecitabine—esophageal cancer	0.00212	0.00458	CcSEcCtD
Glimepiride—Tremor—Capecitabine—esophageal cancer	0.00211	0.00455	CcSEcCtD
Glimepiride—Anaemia—Capecitabine—esophageal cancer	0.00208	0.00449	CcSEcCtD
Glimepiride—CYP2C9—Constitutive Androstane Receptor Pathway—CYP2A6—esophageal cancer	0.00206	0.0094	CbGpPWpGaD
Glimepiride—Sweating—Methotrexate—esophageal cancer	0.00205	0.00444	CcSEcCtD
Glimepiride—Feeling abnormal—Cisplatin—esophageal cancer	0.00205	0.00443	CcSEcCtD
Glimepiride—Leukopenia—Capecitabine—esophageal cancer	0.00201	0.00435	CcSEcCtD
Glimepiride—Agranulocytosis—Methotrexate—esophageal cancer	0.002	0.00432	CcSEcCtD
Glimepiride—Palpitations—Capecitabine—esophageal cancer	0.00199	0.0043	CcSEcCtD
Glimepiride—Loss of consciousness—Capecitabine—esophageal cancer	0.00198	0.00427	CcSEcCtD
Glimepiride—CYP2C9—Arachidonic acid metabolism—ALOX15—esophageal cancer	0.00197	0.009	CbGpPWpGaD
Glimepiride—Hypertension—Capecitabine—esophageal cancer	0.00194	0.0042	CcSEcCtD
Glimepiride—Hepatitis—Methotrexate—esophageal cancer	0.00192	0.00416	CcSEcCtD
Glimepiride—Anxiety—Capecitabine—esophageal cancer	0.00191	0.00412	CcSEcCtD
Glimepiride—Dry mouth—Capecitabine—esophageal cancer	0.00187	0.00405	CcSEcCtD
Glimepiride—Visual impairment—Methotrexate—esophageal cancer	0.00185	0.00401	CcSEcCtD
Glimepiride—Confusional state—Capecitabine—esophageal cancer	0.00185	0.004	CcSEcCtD
Glimepiride—Hypersensitivity—Cisplatin—esophageal cancer	0.00183	0.00397	CcSEcCtD
Glimepiride—Erythema multiforme—Methotrexate—esophageal cancer	0.00182	0.00393	CcSEcCtD
Glimepiride—Shock—Capecitabine—esophageal cancer	0.0018	0.0039	CcSEcCtD
Glimepiride—Thrombocytopenia—Capecitabine—esophageal cancer	0.0018	0.00388	CcSEcCtD
Glimepiride—Tachycardia—Capecitabine—esophageal cancer	0.00179	0.00387	CcSEcCtD
Glimepiride—Asthenia—Cisplatin—esophageal cancer	0.00179	0.00386	CcSEcCtD
Glimepiride—Hyperhidrosis—Capecitabine—esophageal cancer	0.00177	0.00384	CcSEcCtD
Glimepiride—Anorexia—Capecitabine—esophageal cancer	0.00175	0.00378	CcSEcCtD
Glimepiride—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP26A1—esophageal cancer	0.00175	0.00798	CbGpPWpGaD
Glimepiride—CYP2C9—Phase 1 - Functionalization of compounds—ADH7—esophageal cancer	0.00174	0.00794	CbGpPWpGaD
Glimepiride—CYP2C9—Oxidation by Cytochrome P450—CYP26A1—esophageal cancer	0.00173	0.00788	CbGpPWpGaD
Glimepiride—Hypotension—Capecitabine—esophageal cancer	0.00171	0.00371	CcSEcCtD
Glimepiride—Diarrhoea—Cisplatin—esophageal cancer	0.0017	0.00368	CcSEcCtD
Glimepiride—Malnutrition—Methotrexate—esophageal cancer	0.00167	0.00362	CcSEcCtD
Glimepiride—Erythema—Methotrexate—esophageal cancer	0.00167	0.00362	CcSEcCtD
Glimepiride—Insomnia—Capecitabine—esophageal cancer	0.00166	0.00359	CcSEcCtD
Glimepiride—Paraesthesia—Capecitabine—esophageal cancer	0.00165	0.00356	CcSEcCtD
Glimepiride—Dyspnoea—Capecitabine—esophageal cancer	0.00164	0.00354	CcSEcCtD
Glimepiride—Dyspepsia—Capecitabine—esophageal cancer	0.00161	0.00349	CcSEcCtD
Glimepiride—Decreased appetite—Capecitabine—esophageal cancer	0.00159	0.00345	CcSEcCtD
Glimepiride—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.00158	0.00343	CcSEcCtD
Glimepiride—Vomiting—Cisplatin—esophageal cancer	0.00158	0.00342	CcSEcCtD
Glimepiride—Fatigue—Capecitabine—esophageal cancer	0.00158	0.00342	CcSEcCtD
Glimepiride—Vision blurred—Methotrexate—esophageal cancer	0.00158	0.00341	CcSEcCtD
Glimepiride—Rash—Cisplatin—esophageal cancer	0.00157	0.00339	CcSEcCtD
Glimepiride—Dermatitis—Cisplatin—esophageal cancer	0.00157	0.00339	CcSEcCtD
Glimepiride—ABCC8—Neuronal System—GNG7—esophageal cancer	0.00157	0.00715	CbGpPWpGaD
Glimepiride—Anaemia—Methotrexate—esophageal cancer	0.00155	0.00334	CcSEcCtD
Glimepiride—CYP2C9—Phase 1 - Functionalization of compounds—ADH1B—esophageal cancer	0.00152	0.00696	CbGpPWpGaD
Glimepiride—KCNJ11—Neuronal System—GNG7—esophageal cancer	0.00152	0.00694	CbGpPWpGaD
Glimepiride—Feeling abnormal—Capecitabine—esophageal cancer	0.00151	0.00327	CcSEcCtD
Glimepiride—ABCC8—Transmembrane transport of small molecules—SLC10A2—esophageal cancer	0.0015	0.00686	CbGpPWpGaD
Glimepiride—Gastrointestinal pain—Capecitabine—esophageal cancer	0.0015	0.00324	CcSEcCtD
Glimepiride—Leukopenia—Methotrexate—esophageal cancer	0.0015	0.00324	CcSEcCtD
Glimepiride—Nausea—Cisplatin—esophageal cancer	0.00148	0.0032	CcSEcCtD
Glimepiride—ABCC8—Neuronal System—ALDH2—esophageal cancer	0.00147	0.0067	CbGpPWpGaD
Glimepiride—Urticaria—Capecitabine—esophageal cancer	0.00146	0.00315	CcSEcCtD
Glimepiride—Abdominal pain—Capecitabine—esophageal cancer	0.00145	0.00314	CcSEcCtD
Glimepiride—Convulsion—Methotrexate—esophageal cancer	0.00145	0.00314	CcSEcCtD
Glimepiride—KCNJ11—Neuronal System—ALDH2—esophageal cancer	0.00142	0.0065	CbGpPWpGaD
Glimepiride—CYP2C9—Phase 1 - Functionalization of compounds—CYP26A1—esophageal cancer	0.00142	0.00647	CbGpPWpGaD
Glimepiride—ABCC8—Transmembrane transport of small molecules—ATP1B2—esophageal cancer	0.00141	0.00645	CbGpPWpGaD
Glimepiride—Confusional state—Methotrexate—esophageal cancer	0.00138	0.00298	CcSEcCtD
Glimepiride—CYP2C9—Constitutive Androstane Receptor Pathway—ABCB1—esophageal cancer	0.00137	0.00624	CbGpPWpGaD
Glimepiride—CYP2C9—Arachidonic acid metabolism—PTGS1—esophageal cancer	0.00137	0.00624	CbGpPWpGaD
Glimepiride—Anaphylactic shock—Methotrexate—esophageal cancer	0.00137	0.00295	CcSEcCtD
Glimepiride—Hypersensitivity—Capecitabine—esophageal cancer	0.00135	0.00292	CcSEcCtD
Glimepiride—ABCC8—Transmembrane transport of small molecules—SLC39A6—esophageal cancer	0.00134	0.00611	CbGpPWpGaD
Glimepiride—Thrombocytopenia—Methotrexate—esophageal cancer	0.00134	0.00289	CcSEcCtD
Glimepiride—Hyperhidrosis—Methotrexate—esophageal cancer	0.00132	0.00286	CcSEcCtD
Glimepiride—Asthenia—Capecitabine—esophageal cancer	0.00132	0.00285	CcSEcCtD
Glimepiride—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—esophageal cancer	0.0013	0.00595	CbGpPWpGaD
Glimepiride—Anorexia—Methotrexate—esophageal cancer	0.0013	0.00282	CcSEcCtD
Glimepiride—Pruritus—Capecitabine—esophageal cancer	0.0013	0.00281	CcSEcCtD
Glimepiride—ABCC8—Transmembrane transport of small molecules—AQP3—esophageal cancer	0.00128	0.00583	CbGpPWpGaD
Glimepiride—Hypotension—Methotrexate—esophageal cancer	0.00128	0.00276	CcSEcCtD
Glimepiride—Diarrhoea—Capecitabine—esophageal cancer	0.00125	0.00271	CcSEcCtD
Glimepiride—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2A6—esophageal cancer	0.00125	0.00569	CbGpPWpGaD
Glimepiride—Insomnia—Methotrexate—esophageal cancer	0.00123	0.00267	CcSEcCtD
Glimepiride—CYP2C9—Oxidation by Cytochrome P450—CYP2A6—esophageal cancer	0.00123	0.00561	CbGpPWpGaD
Glimepiride—Paraesthesia—Methotrexate—esophageal cancer	0.00123	0.00265	CcSEcCtD
Glimepiride—ABCC8—Transmembrane transport of small molecules—SLC30A7—esophageal cancer	0.00122	0.00559	CbGpPWpGaD
Glimepiride—ABCC8—Transmembrane transport of small molecules—ATP4A—esophageal cancer	0.00122	0.00559	CbGpPWpGaD
Glimepiride—Dyspnoea—Methotrexate—esophageal cancer	0.00122	0.00263	CcSEcCtD
Glimepiride—Somnolence—Methotrexate—esophageal cancer	0.00121	0.00263	CcSEcCtD
Glimepiride—Dizziness—Capecitabine—esophageal cancer	0.00121	0.00262	CcSEcCtD
Glimepiride—Dyspepsia—Methotrexate—esophageal cancer	0.0012	0.0026	CcSEcCtD
Glimepiride—Decreased appetite—Methotrexate—esophageal cancer	0.00119	0.00257	CcSEcCtD
Glimepiride—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.00118	0.00255	CcSEcCtD
Glimepiride—Fatigue—Methotrexate—esophageal cancer	0.00118	0.00255	CcSEcCtD
Glimepiride—Vomiting—Capecitabine—esophageal cancer	0.00117	0.00252	CcSEcCtD
Glimepiride—CYP2C9—Arachidonic acid metabolism—CYP1B1—esophageal cancer	0.00116	0.0053	CbGpPWpGaD
Glimepiride—Rash—Capecitabine—esophageal cancer	0.00116	0.0025	CcSEcCtD
Glimepiride—Dermatitis—Capecitabine—esophageal cancer	0.00116	0.0025	CcSEcCtD
Glimepiride—Headache—Capecitabine—esophageal cancer	0.00115	0.00249	CcSEcCtD
Glimepiride—Feeling abnormal—Methotrexate—esophageal cancer	0.00113	0.00243	CcSEcCtD
Glimepiride—Gastrointestinal pain—Methotrexate—esophageal cancer	0.00112	0.00241	CcSEcCtD
Glimepiride—Nausea—Capecitabine—esophageal cancer	0.00109	0.00236	CcSEcCtD
Glimepiride—Urticaria—Methotrexate—esophageal cancer	0.00108	0.00235	CcSEcCtD
Glimepiride—Abdominal pain—Methotrexate—esophageal cancer	0.00108	0.00233	CcSEcCtD
Glimepiride—CYP2C9—Phase 1 - Functionalization of compounds—ALDH2—esophageal cancer	0.00107	0.0049	CbGpPWpGaD
Glimepiride—CYP2C9—Phase 1 - Functionalization of compounds—CYP2A6—esophageal cancer	0.00101	0.00461	CbGpPWpGaD
Glimepiride—Hypersensitivity—Methotrexate—esophageal cancer	0.00101	0.00218	CcSEcCtD
Glimepiride—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1B1—esophageal cancer	0.001	0.00458	CbGpPWpGaD
Glimepiride—CYP2C9—Oxidation by Cytochrome P450—CYP1B1—esophageal cancer	0.000991	0.00452	CbGpPWpGaD
Glimepiride—Asthenia—Methotrexate—esophageal cancer	0.00098	0.00212	CcSEcCtD
Glimepiride—Pruritus—Methotrexate—esophageal cancer	0.000966	0.00209	CcSEcCtD
Glimepiride—CYP2C9—Phase 1 - Functionalization of compounds—PTGS1—esophageal cancer	0.000957	0.00437	CbGpPWpGaD
Glimepiride—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP19A1—esophageal cancer	0.000944	0.00431	CbGpPWpGaD
Glimepiride—Diarrhoea—Methotrexate—esophageal cancer	0.000934	0.00202	CcSEcCtD
Glimepiride—CYP2C9—Oxidation by Cytochrome P450—CYP19A1—esophageal cancer	0.000932	0.00425	CbGpPWpGaD
Glimepiride—ABCC8—Transmembrane transport of small molecules—ABCC2—esophageal cancer	0.000928	0.00424	CbGpPWpGaD
Glimepiride—CYP2C9—Biological oxidations—ADH7—esophageal cancer	0.000923	0.00422	CbGpPWpGaD
Glimepiride—Dizziness—Methotrexate—esophageal cancer	0.000903	0.00195	CcSEcCtD
Glimepiride—Vomiting—Methotrexate—esophageal cancer	0.000868	0.00188	CcSEcCtD
Glimepiride—Rash—Methotrexate—esophageal cancer	0.000861	0.00186	CcSEcCtD
Glimepiride—Dermatitis—Methotrexate—esophageal cancer	0.00086	0.00186	CcSEcCtD
Glimepiride—Headache—Methotrexate—esophageal cancer	0.000855	0.00185	CcSEcCtD
Glimepiride—ABCC8—Transmembrane transport of small molecules—GNG7—esophageal cancer	0.000842	0.00385	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—BLVRB—esophageal cancer	0.000828	0.00378	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—SLC52A3—esophageal cancer	0.000828	0.00378	CbGpPWpGaD
Glimepiride—CYP2C9—Phase 1 - Functionalization of compounds—CYP1B1—esophageal cancer	0.000814	0.00372	CbGpPWpGaD
Glimepiride—Nausea—Methotrexate—esophageal cancer	0.000811	0.00175	CcSEcCtD
Glimepiride—CYP2C9—Biological oxidations—ADH1B—esophageal cancer	0.00081	0.0037	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—BLVRB—esophageal cancer	0.000803	0.00366	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—SLC52A3—esophageal cancer	0.000803	0.00366	CbGpPWpGaD
Glimepiride—CYP2C9—Phase 1 - Functionalization of compounds—CYP19A1—esophageal cancer	0.000765	0.00349	CbGpPWpGaD
Glimepiride—CYP2C9—Biological oxidations—CYP26A1—esophageal cancer	0.000753	0.00344	CbGpPWpGaD
Glimepiride—CYP2C9—Metapathway biotransformation—CYP26A1—esophageal cancer	0.000742	0.00339	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—SLC10A2—esophageal cancer	0.000704	0.00321	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—CA1—esophageal cancer	0.000704	0.00321	CbGpPWpGaD
Glimepiride—CYP2C9—Biological oxidations—GSTO1—esophageal cancer	0.0007	0.0032	CbGpPWpGaD
Glimepiride—CYP2C9—Metapathway biotransformation—GSTO1—esophageal cancer	0.00069	0.00315	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—SLC10A2—esophageal cancer	0.000682	0.00312	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—CA1—esophageal cancer	0.000682	0.00312	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—CA2—esophageal cancer	0.000644	0.00294	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—CA2—esophageal cancer	0.000624	0.00285	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—PLCE1—esophageal cancer	0.000598	0.00273	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—ADH7—esophageal cancer	0.000598	0.00273	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—PLCE1—esophageal cancer	0.00058	0.00265	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—ADH7—esophageal cancer	0.00058	0.00265	CbGpPWpGaD
Glimepiride—CYP2C9—Biological oxidations—ALDH2—esophageal cancer	0.000571	0.0026	CbGpPWpGaD
Glimepiride—CYP2C9—Biological oxidations—GSTT1—esophageal cancer	0.000543	0.00248	CbGpPWpGaD
Glimepiride—CYP2C9—Biological oxidations—CYP2A6—esophageal cancer	0.000536	0.00245	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—ADH1B—esophageal cancer	0.000525	0.0024	CbGpPWpGaD
Glimepiride—CYP2C9—Arachidonic acid metabolism—PTGS2—esophageal cancer	0.000524	0.00239	CbGpPWpGaD
Glimepiride—ABCC8—Transmembrane transport of small molecules—HMOX1—esophageal cancer	0.000513	0.00234	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—ADH1B—esophageal cancer	0.000509	0.00232	CbGpPWpGaD
Glimepiride—CYP2C9—Biological oxidations—PTGS1—esophageal cancer	0.000508	0.00232	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—TYMP—esophageal cancer	0.000501	0.00229	CbGpPWpGaD
Glimepiride—ABCC8—Transmembrane transport of small molecules—ABCB1—esophageal cancer	0.000493	0.00225	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—CYP26A1—esophageal cancer	0.000488	0.00223	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—TYMP—esophageal cancer	0.000486	0.00222	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—ALOX15—esophageal cancer	0.000475	0.00217	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—CYP26A1—esophageal cancer	0.000473	0.00216	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—ALOX15—esophageal cancer	0.000461	0.0021	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—TPI1—esophageal cancer	0.000453	0.00207	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—GSTO1—esophageal cancer	0.000453	0.00207	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—TPI1—esophageal cancer	0.00044	0.00201	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—GSTO1—esophageal cancer	0.00044	0.00201	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—ALDOB—esophageal cancer	0.000435	0.00199	CbGpPWpGaD
Glimepiride—CYP2C9—Biological oxidations—CYP1B1—esophageal cancer	0.000432	0.00197	CbGpPWpGaD
Glimepiride—CYP2C9—Metapathway biotransformation—CYP1B1—esophageal cancer	0.000426	0.00195	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—ALDOB—esophageal cancer	0.000422	0.00192	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—GAPDH—esophageal cancer	0.000419	0.00191	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism of lipids and lipoproteins—SLC10A2—esophageal cancer	0.000417	0.0019	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—CRABP1—esophageal cancer	0.000415	0.00189	CbGpPWpGaD
Glimepiride—CYP2C9—Biological oxidations—CYP19A1—esophageal cancer	0.000407	0.00186	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—GAPDH—esophageal cancer	0.000406	0.00185	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—CRABP1—esophageal cancer	0.000402	0.00184	CbGpPWpGaD
Glimepiride—CYP2C9—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000401	0.00183	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—GNG7—esophageal cancer	0.000395	0.0018	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—GNG7—esophageal cancer	0.000383	0.00175	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—ALDH2—esophageal cancer	0.00037	0.00169	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—ALDH2—esophageal cancer	0.000358	0.00164	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—GSTT1—esophageal cancer	0.000352	0.00161	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—CYP2A6—esophageal cancer	0.000348	0.00159	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—GSTT1—esophageal cancer	0.000341	0.00156	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—CYP2A6—esophageal cancer	0.000337	0.00154	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—PTGS1—esophageal cancer	0.000329	0.0015	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—ENO1—esophageal cancer	0.000329	0.0015	CbGpPWpGaD
Glimepiride—ABCC8—Transmembrane transport of small molecules—CREBBP—esophageal cancer	0.000329	0.0015	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—PSME2—esophageal cancer	0.000325	0.00148	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—PSME1—esophageal cancer	0.000325	0.00148	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—PTGS1—esophageal cancer	0.00032	0.00146	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—ENO1—esophageal cancer	0.00032	0.00146	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—PSME2—esophageal cancer	0.000315	0.00144	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—PSME1—esophageal cancer	0.000315	0.00144	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism of lipids and lipoproteins—ALOX15—esophageal cancer	0.000282	0.00129	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—CYP1B1—esophageal cancer	0.00028	0.00128	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—CYP1B1—esophageal cancer	0.000272	0.00124	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—CYP19A1—esophageal cancer	0.000263	0.0012	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—CYP19A1—esophageal cancer	0.000255	0.00117	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000246	0.00112	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—HMOX1—esophageal cancer	0.00024	0.0011	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—HMOX1—esophageal cancer	0.000233	0.00106	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—ABCB1—esophageal cancer	0.000231	0.00105	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—ABCB1—esophageal cancer	0.000224	0.00102	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—SLC52A3—esophageal cancer	0.000218	0.000997	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—BLVRB—esophageal cancer	0.000218	0.000997	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000195	0.000892	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—CA1—esophageal cancer	0.000186	0.000848	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—SLC10A2—esophageal cancer	0.000186	0.000848	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—CA2—esophageal cancer	0.00017	0.000776	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	0.000166	0.000758	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—PLCE1—esophageal cancer	0.000158	0.000721	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—ADH7—esophageal cancer	0.000158	0.000721	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	0.000156	0.000713	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—CREBBP—esophageal cancer	0.000154	0.000704	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—CREBBP—esophageal cancer	0.00015	0.000683	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—ADH1B—esophageal cancer	0.000138	0.000632	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—NOS3—esophageal cancer	0.000138	0.00063	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—NOS3—esophageal cancer	0.000134	0.000611	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—TYMP—esophageal cancer	0.000132	0.000604	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—CYP26A1—esophageal cancer	0.000129	0.000588	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—PTGS2—esophageal cancer	0.000126	0.000577	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—ALOX15—esophageal cancer	0.000125	0.000573	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—PTGS2—esophageal cancer	0.000122	0.000559	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—GSTO1—esophageal cancer	0.00012	0.000546	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—TPI1—esophageal cancer	0.00012	0.000546	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—ALDOB—esophageal cancer	0.000115	0.000524	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—GAPDH—esophageal cancer	0.00011	0.000504	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—CRABP1—esophageal cancer	0.000109	0.0005	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—EP300—esophageal cancer	0.000105	0.00048	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—GNG7—esophageal cancer	0.000104	0.000475	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—EP300—esophageal cancer	0.000102	0.000465	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—ALDH2—esophageal cancer	9.76e-05	0.000445	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—GSTT1—esophageal cancer	9.28e-05	0.000424	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—CYP2A6—esophageal cancer	9.17e-05	0.000419	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	9.14e-05	0.000417	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—ENO1—esophageal cancer	8.7e-05	0.000397	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—PTGS1—esophageal cancer	8.7e-05	0.000397	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—PSME1—esophageal cancer	8.57e-05	0.000391	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—PSME2—esophageal cancer	8.57e-05	0.000391	CbGpPWpGaD
Glimepiride—ABCC8—Metabolism—PIK3CA—esophageal cancer	7.77e-05	0.000355	CbGpPWpGaD
Glimepiride—KCNJ11—Metabolism—PIK3CA—esophageal cancer	7.53e-05	0.000344	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	7.48e-05	0.000342	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—CYP1B1—esophageal cancer	7.39e-05	0.000338	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—CYP19A1—esophageal cancer	6.95e-05	0.000317	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—HMOX1—esophageal cancer	6.34e-05	0.00029	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	6.22e-05	0.000284	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—ABCB1—esophageal cancer	6.09e-05	0.000278	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	4.6e-05	0.00021	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—CREBBP—esophageal cancer	4.07e-05	0.000186	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—NOS3—esophageal cancer	3.64e-05	0.000166	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—PTGS2—esophageal cancer	3.33e-05	0.000152	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—EP300—esophageal cancer	2.77e-05	0.000127	CbGpPWpGaD
Glimepiride—CYP2C9—Metabolism—PIK3CA—esophageal cancer	2.05e-05	9.36e-05	CbGpPWpGaD
